Predictors included in the models were matched to variables in RE-LY. Data on genetic factors were not available in RE-LY and were discarded. We applied the original regression equations to the Background and Purpose-Performance of risk scores for major bleeding in patients with atrial fibrillation and a previous transient ischemic attack or ischemic stroke is not well established. We aimed to validate risk scores for major bleeding in patients with atrial fibrillation treated with oral anticoagulants after cerebral ischemia and explore the net benefit of oral anticoagulants among bleeding risk categories. Methods-We analyzed 3623 patients with a history of transient ischemic attack or stroke included in the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). We assessed performance of HEMORR 2 HAGES (hepatic or renal disease, ethanol abuse, malignancy, older age, reduced platelet count or function, hypertension [uncontrolled], anemia, genetic factors, excessive fall risk, and stroke), Shireman, HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly), ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation), and ORBIT scores (older age, reduced haemoglobin/haematocrit/history of anaemia, bleeding history, insufficient kidney function, and treatment with antiplatelet) with C statistics and calibration plots. Net benefit of oral anticoagulants was explored by comparing risk reduction in ischemic stroke with risk increase in major bleedings on warfarin. Results-During 6922 person-years of follow-up, 266 patients experienced a major bleed (3.8 per 100 person-years). C statistics ranged from 0.62 (Shireman) to 0.67 (ATRIA). Calibration was poor for ATRIA and moderate for other models. The reduction in recurrent ischemic strokes on warfarin was larger than the increase in major bleeding risk, irrespective of bleeding risk category. Conclusions-Performance of prediction models for major bleeding in patients with cerebral ischemia and atrial fibrillation is modest but comparable with performance in patients with only atrial fibrillation. Bleeding risk scores cannot guide treatment decisions for oral anticoagulants but may still be useful to identify modifiable risk factors for bleeding. Clinical usefulness may be best for ORBIT, which is based on a limited number of easily obtainable variables and showed reasonable performance.
T he benefit of prevention with oral anticoagulants (OAC) is partially offset by an increased risk of bleeding. 1 Risk scores have been developed to assess stroke and bleeding risk for individual patients with atrial fibrillation (AF), 2, 3 helping physicians to weigh benefits and risks of OAC.
Patients with AF and a previous transient ischemic attack (TIA) or ischemic stroke form a distinct group because they have a high risk of recurrent stroke 4 and a high risk of bleeding, including intracranial hemorrhage. 5 Performance of risk scores for major bleeding in patients with a previous stroke is not well established. We aimed to externally validate existing risk scores for major bleeding in patients with a TIA or ischemic stroke on OAC and explore the net benefit of OAC among bleeding risk categories.
Methods
We used a previously published literature review to identify existing prediction models for major bleeding in patients with AF 6 and performed an additional search in PubMed to identify models published after 2012 (online-only Data Supplement). We validated available models in patients with a previous TIA or stroke included in the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). 7 RE-LY included patients with documented AF in the preceding 6 months and 1 additional risk factor and randomized patients to dabigatran (110/150 mg BID) or warfarin. Between 2005 and 2007, 18 113 patients were included of whom 3623 had a history of TIA or stroke. The median followup duration was 2 years. The primary safety outcome was major bleeding, defined as reduction in hemoglobin level ≥20 g/L, transfusion of ≥2 U of blood or symptomatic bleeding in a critical area or organ. RE-LY was approved by the institutional review board of each participating center. validation data to calculate the predicted 1-and 2-year probability of major bleeding for each patient. If the regression equation was unavailable, we validated the score chart. Model performance was assessed with the C statistic and calibration plots. If predicted risks were not reported, rates per 100 person-years were used. Performance of models was also assessed separately for patients on dabigatran and warfarin. We explored whether the net benefit of treatment with warfarin differed among bleeding risk categories, by comparing the reduction in ischemic strokes and increase in major bleedings attributable to warfarin (online-only Data Supplement). Analyses were performed with R version 3.3.0. Results are reported in accordance with the TRIPOD statement (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis).
Results
We identified 6 risk scores for major bleeding in patients with AF: 4 from a previously published literature review 3, [8] [9] [10] and 2 from our additional search 11, 12 (Table I in the online-only Data Supplement). Frequently included predictors were age, prior bleeding, anemia, and renal failure (Table II in the onlineonly Data Supplement). Five models could be validated; one required information on biomarkers, 11 which was not available in RE-LY.
Baseline characteristics of the development and validation cohorts are presented in Table III in the online-only Data Supplement. During 6922 person-years of follow-up, 266 major bleedings occurred (rate, 3.8; 95% confidence interval, 3.4-4.3 per 100 person-years). C statistics ranged from 0.62 to 0.67 at 1 year (Table) and were comparable at 2 years (Table IV in the online-only Data Supplement). Discriminatory performance of all models was better among patients randomized to dabigatran than warfarin (Table) . At 1 year, calibration was reasonable for most scores, apart from ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation), which underestimated major bleeding risk ( Figure I in the online-only Data Supplement). ORBIT (older age, reduced haemoglobin/haematocrit/history of anaemia, bleeding history, insufficient kidney function, and treatment with antiplatelet) showed best calibration at 2 years ( Figure II in the online-only Data Supplement). Risk stratification capacity of each score across risk groups is shown in Figure 1 . Figure 2 shows that the reduction in recurrent ischemic strokes with warfarin treatment is larger than the increase in major bleeds, irrespective of bleeding risk category ( Figure III 
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Discussion
Predictive performance of risk scores for major bleeding in patients with AF is modest in patients with a previous TIA or ischemic stroke. Irrespective of bleeding risk, the benefits of OAC seem to outweigh the risks. The moderate performance of models in our study is in line with results from previous studies among patients with AF. C statistics ranged from 0.63 to 0.72 in the original development cohorts of included models and did not exceed 0.65 in most external validation studies. 6, 13 The comparable discriminatory performance indicates that predictor-outcome associations are largely similar for patients with and without a previous stroke or TIA. The lower C statistic found in warfarin-treated patients may partly be explained by quality of international normalized ratio control-an important determinant for bleeding. Further refinement of risk scores for patients with cerebral ischemia might be achieved by incorporating radiological characteristics, including presence of microbleeds or leukoairaiosis, which are known to be strongly associated with intracranial bleeding. 14, 15 However, the uptake of a risk score in clinical practice may, next to its performance, also be influenced by its ease of use. This may be best for ATRIA and ORBIT, which are based on a small number of readily available variables.
The benefits of OAC outweighed harms in all bleeding risk groups and risk scores should, therefore, not be used to guide treatment decisions for OAC. This is in keeping with recommendations in current guidelines, stating that all patients with previous stroke qualify for such treatment. However, assessment of bleeding risk may still be useful to identify modifiable risk factors for bleeding, as well as to identify high-risk patients who might qualify for treatment with gastroprotective agents.
Our study benefits from high-quality data, with detailed follow-up and independent adjudication of bleeds. A limitation is that we used trial data for external validation. Patients at the highest risk of bleeding have been excluded from RE-LY, and absolute risks may have been underestimated. Furthermore, patients with a stroke in the previous 2 weeks were excluded; therefore, generalizability to patients with acute stroke is unknown.
In conclusion, prediction models for major bleeding in patients with AF show modest performance in patients with cerebral ischemia and AF, but performance is comparable with that in patients with AF in general. Clinical usefulness may be best for ORBIT, which is based on a limited number of variables and showed reasonable discrimination and calibration. Figure 2 . Risk reduction in ischemic stroke by warfarin treatment, and risk increase in major bleeding, per bleeding risk category of the ORBIT score.
